Tucatinib/tucatinib and pyrotinib: introduction and comparison of two HER2-targeted drugs

Tucatinib/Tucatinib and pyrotinib are two oral tyrosine kinase inhibitors used to treat HER2-positive breast cancer.

Tucatinib and pyrotinib are both first-generation oral tyrosine kinase inhibitors that block the activation of the HER2 signaling pathway by inhibiting the tyrosine kinase activity on the HER2 receptor. This can inhibit the growth and proliferation of cancer cells and reduce the size of tumors. Tucatinib has shown good efficacy in clinical trials. Studies have shown that in patients with HER2-positive metastatic breast cancer combined with triple-negative breast cancer, adding tucatinib to trastuzumab and chemotherapy can significantly extend the patient's progression-free survival and overall survival, while also improving the patient's quality of life.

Pyrotinib is also a new oral tyrosine kinase inhibitor currently undergoing clinical trials. Preliminary research results show that pyrotinib has a significant inhibitory effect onHER2-positive breast cancer, and when used in combination with chemotherapy drugs, the treatment effect can be further improved.

Although tucatinib and pyrotinib are both tyrosine kinase inhibitors, their structures and mechanisms of action are slightly different. This also means there may be differences in patient selection. Therefore, for patients with HER2-positive breast cancer, the selection of appropriate oral tyrosine kinase inhibitors needs to be based on individual circumstances and physician recommendations.

In summary, tucatinib and pyrotinib are two new oral tyrosine kinase inhibitors that have important clinical significance in the treatment of HER2-positive breast cancer. Their development provides patients with more treatment options, helping to extend their survival and improve their quality of life. It is important to note that patients should follow their doctor's instructions when using these drugs and undergo regular monitoring and follow-up.